QIAGEN N.V. $QGEN Shares Purchased by Johnson Investment Counsel Inc.

Johnson Investment Counsel Inc. boosted its stake in shares of QIAGEN N.V. (NYSE:QGEN) by 0.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 57,119 shares of the company’s stock after buying an additional 519 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in QIAGEN were worth $2,745,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. SVB Wealth LLC purchased a new position in QIAGEN during the first quarter worth about $31,000. Farther Finance Advisors LLC boosted its stake in QIAGEN by 400.5% during the second quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock worth $51,000 after buying an additional 849 shares during the period. Hilltop National Bank purchased a new position in QIAGEN during the second quarter worth about $66,000. ANTIPODES PARTNERS Ltd purchased a new position in QIAGEN during the first quarter worth about $94,000. Finally, GAMMA Investing LLC boosted its stake in QIAGEN by 93.9% during the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company’s stock worth $118,000 after buying an additional 1,425 shares during the period. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Analysts Set New Price Targets

QGEN has been the subject of several research analyst reports. Wall Street Zen lowered shares of QIAGEN from a “buy” rating to a “hold” rating in a research note on Saturday. Barclays set a $53.00 target price on shares of QIAGEN and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. UBS Group increased their target price on shares of QIAGEN from $48.00 to $50.00 and gave the stock a “neutral” rating in a research note on Thursday, August 7th. Cowen reissued a “hold” rating on shares of QIAGEN in a research note on Thursday, August 7th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of QIAGEN in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, QIAGEN presently has an average rating of “Hold” and a consensus price target of $49.40.

QIAGEN Trading Up 1.0%

NYSE QGEN opened at $47.30 on Tuesday. The firm has a 50 day simple moving average of $47.05 and a 200-day simple moving average of $45.63. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. QIAGEN N.V. has a one year low of $37.63 and a one year high of $51.88. The firm has a market cap of $10.51 billion, a price-to-earnings ratio of 27.95, a PEG ratio of 2.46 and a beta of 0.66.

QIAGEN (NYSE:QGEN) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, meeting the consensus estimate of $0.60. The business had revenue of $533.54 million during the quarter, compared to analyst estimates of $523.97 million. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.55 earnings per share. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Equities research analysts anticipate that QIAGEN N.V. will post 2.26 EPS for the current fiscal year.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.